



an Open Access Journal by MDPI

Bacteriophage Therapy: Recent Developments and Applications of a Renaissance Weapon

Guest Editors:

Dr. Aneta Skaradzińska

Department of Biotechnology and Food Microbiology, Faculty of Biotechnology and Food Science, Wrocław University of Environmental and Life Sciences, Chelmońskiego 37, 51-630 Wrocław, Poland

Dr. Anna Nowaczek

Department of Veterinary Prevention and Avian Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Głęboka 30, 20-612 Lublin, Poland

Message from the Guest Editors

Bacteriophages have been used to treat bacterial infections nearly since the moment of their discovery at the beginning of the 20th century. However, overshadowed by antibiotics, phage therapy has been marginalized for decades. Nowadays, with the rapidly growing number of drug-resistant bacterial strains, phage therapy becomes one of the most promising alternatives to classical methods of treatment. Moreover, studies on bacterial viruses are not limited to human or veterinary medicine but increasingly reach new fields of biotechnology.

Deadline for manuscript submissions:

closed (31 December 2023)



mdpi.com/si/112950

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi